The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.
本发明涉及式I-II的化合物及其药学上可接受的互变异构体、盐或立体异构体,这些化合物是syk和/或JAK激酶的
抑制剂。本发明还涉及用于制备这类化合物的中间体,制备这种化合物,含有这种化合物的药物组合物,抑制syk和/或JAK激酶活性的方法,抑制血小板聚集的方法,以及预防或治疗由syk和/或JAK激酶活性至少部分介导的多种疾病的方法,如心血管疾病、炎症性疾病、自身免疫疾病和细胞增殖障碍、血栓形成、过敏、哮喘、类风湿关节炎、白血病或非霍奇
金淋巴瘤。